The latest price target for Outlook Therapeutics (NASDAQ:OTLK) was reported by HC Wainwright & Co. on September 30, 2025. The analyst firm set a price target for $1.00 expecting OTLK to fall to within 12 months (a possible -53.78% downside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Outlook Therapeutics (NASDAQ:OTLK) was provided by HC Wainwright & Co., and Outlook Therapeutics reiterated their neutral rating.

The last upgrade for Outlook Therapeutics Inc happened on March 27, 2024 when BTIG raised their price target to $50. BTIG previously had a neutral for Outlook Therapeutics Inc.

The last downgrade for Outlook Therapeutics Inc happened on August 29, 2025 when Guggenheim changed their price target from N/A to N/A for Outlook Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outlook Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outlook Therapeutics was filed on September 30, 2025 so you should expect the next rating to be made available sometime around September 30, 2026.

While ratings are subjective and will change, the latest Outlook Therapeutics (OTLK) rating was a reiterated with a price target of $1.00 to $1.00. The current price Outlook Therapeutics (OTLK) is trading at is $2.16, which is out of the analyst’s predicted range.